The result of the Wegovy test gives an increase in novo nordisk against the background of the US disaster

New trial data suggest Novo nordiskVegova weight loss drugs are eliminated by competitive heart reduction procedures, in good news for the Danish pharmaceutical giant because it fights a stock market.

The company on Sunday said the further use of the weight management, which is sold to consumers as Wegovy, has led to 57% more risk of heart attack, stroke in obese and cardiovascular disease or overweight compared to Tirceptide users.

Tirzepatide – an active substance in Zepbound and Mounjaro, drugs made by an American firm Eli Lily -The head competitor Novo Nordisk in the Battle of creating leading market therapies.

The company noted that the results occurred with a real study unlike randomized control test, which is a “gold standard” to assess the effectiveness of treatment. The number of patients who record such events was also very low, reaching 0.1% for those who use vegov and 0.4% for those on Tirzepatid.

However, the company said the study is added to “increasing evidence, suggesting that heart benefits observed in Wegovy are characteristic of semaglutid molecules and therefore cannot be spread to other treatments based on GLP-1 or GIP/GLP-1”.

GLP-1, or glucagon-like agonists of the peptide-1 receptor, refers to a range of drugs used to treat type 2 diabetes and obesity, mimicing the hormones formed in the intestine to suppress human appetite and regulate blood sugar. These include known semaglutide based on Semaglutide Novo, developed as type 2 diabetes treatment.

Huge weight gain in weight loss in recent years has attracted investors to the current hunt for both presenters and for leading medicines and Potential new applicants.

Test data on the impact of various drugs on weight loss and on a number of other conditions – from the heart of the condition. liver and Alzheimer’s disease by Apnea sleep and Alcohol addiction – He often was a catalyst for stock value. Recently traders evaluate Eli Lily’s efforts and Novo Nordisk Development of oral obesity pillsRemoval of the need for injection.

Novo Nordisk shares were about 3% higher on Monday.

Michael Field, the main strategist in Morningstar, said a significant reduction in the risk of heart attacks provided by the vegovi could become a potential “game change” for Novo Nordisk, but that the reaction on Monday showed that the market is “encouraged but is not fond of”.

“It is important to remember that this is just trial data, and rivals have a long history to overtake each other again, and again. This is said to be one of the cheapest in Europe, and investors are not particularly given large traditional pharmaceutical giants. by e -mail.

Berry’s tire, health analyst at Quilter Cheviot, said the latest data on heart disease could be a “positive development” for Novo Nordisk, but that it is impossible to make any solid conclusions about comparing Wegovy vs Tirzepatide in the battle between Novo Nordisk and Eli Lilly. “

“After a tough period, it helps Novo Nordisk in terms of promotion. Thus, today shares have grown after a difficult period, and investors will closely monitor whether such events act as a catalyst for improvement,” Berry said.

Since then, it has lost this title, after which the stock price decreased by 10.6% in 2024 and 40% in 2025 today. Denmark last week more than halved Its annual economic growth forecast is partly referring to the decline in the US market share and expectations for lower pharmaceutical exports.

Novo Nordisk was uncertain about the sector around the tariffs on the White House and US President Donald Trump Click to force firms to reduce drug prices and move state production. Global Competition in Space Space continues to grow and companies also face the problem A copation of the connected procedures.

Novo last month reported the huge annual sales growth in its Profit in the second quarterHowever, he stated the weaker growth forecasts in the second half and stated that it would be focused on sales directly to consumers to combat the problem of copying.

Denmark last week more than halved Its annual economic growth forecast, partly referring to the decline in Novo Nordisk growth expectations. Economic Ministry of the country stated that while companies such as Novo Nordisk EUThere is “a considerable degree of unpredictability related to the US administration policy”.

Analysts said CNBC last month that European pharmaceutical shares were unable to rally on the news trade transaction because investors were alert about permanent White House Section 232 Study On the impact of various imports on the US national security, including pharmaceuticals.

In a note last week’s UBS analysts stated that after Mov in May on US Pharmacy Networks CVS to expand access to WegovyThey “began to see the growth of potentially plateau” for drugs. It was in lines with previous expectations, “given the constant connectors and relatively strong Zepbound characteristics,” they added.

– Karen Gilchrist CNBC contributed to this story.